ODCM
CRSP icon

Old Dominion Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Old Dominion Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$207K Hold
1,850
– – 0.04% 166
2021
Q2 		$299K Hold
1,850
– – 0.06% 148
2021
Q1 		$225K Hold
1,850
– – 0.05% 162
2020
Q4 		$283K Buy
+1,850
New +$219K 0.07% 140

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Old Dominion Capital Management's CRSP Position: Q3 2021 in Review

Old Dominion Capital Management held its CRISPR Therapeutics (CRSP) position steady in Q3 2021 at 1,850 shares worth $207K. The position accounts for 0.04% of the portfolio, ranked #166.

Old Dominion Capital Management first reported a position in CRSP in Q4 2020 and has held it in 4 quarters since. The position peaked at $299K in Q2 2021. 473 funds tracked by Wall St. Rank hold CRSP as of Q3 2021.

  • Old Dominion Capital Management held 1,850 shares of CRISPR Therapeutics worth $207K as of Q3 2021.
  • Old Dominion Capital Management left its CRISPR Therapeutics share count unchanged in Q3 2021.
  • CRISPR Therapeutics made up 0.04% of Old Dominion Capital Management's portfolio in Q3 2021, its #166 holding.
  • Old Dominion Capital Management first reported a position in CRISPR Therapeutics in Q4 2020 and has held it in 4 quarters since.
  • Old Dominion Capital Management's CRISPR Therapeutics position peaked at $299K in Q2 2021.
  • 473 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2021.

Based on Old Dominion Capital Management's 13F filing for Q3 2021, filed 8 Oct 2021.